Advertisement
U.S. markets closed
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow 30

    39,087.38
    +90.99 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.02 (+1.14%)
     
  • Russell 2000

    2,076.39
    +21.55 (+1.05%)
     
  • Crude Oil

    79.81
    +1.55 (+1.98%)
     
  • Gold

    2,091.60
    +36.90 (+1.80%)
     
  • Silver

    23.25
    +0.58 (+2.58%)
     
  • EUR/USD

    1.0839
    +0.0032 (+0.29%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • GBP/USD

    1.2655
    +0.0029 (+0.23%)
     
  • USD/JPY

    150.0640
    +0.0800 (+0.05%)
     
  • Bitcoin USD

    61,916.09
    +41.07 (+0.07%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

EXCLUSIVE: Ocean Biomedical's Co-Founder Jack Elias To Receive US Patent For Lung Fibrosis Therapeutics

Ocean Biomedical Inc's (NASDAQ: OCEA) co-founder Jack Elias, received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for his U.S. patent application covering a therapeutic molecule for pulmonary fibrosis.

What Happened: This patent allowance covers pulmonary fibrosis caused by multiple conditions, including idiopathic pulmonary fibrosis (IPF), genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome (HPS), chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases, including asbestosis and silicosis.

Ocean Biomedical anticipates that the USPTO will issue a patent in the coming months.

Discoveries in recent years by Dr. Elias and his colleagues at Brown University have revealed a new target and a new pathway for treating pulmonary tissue damage in Idiopathic Pulmonary Fibrosis (IPF).

Why It Matters: IPF is a lung condition affecting about 100,000 people per year in the U.S. and about 15 per 100,000 people worldwide, with a much higher prevalence in males over 50 years.

Ocean Biomedical's approach to treating pulmonary fibrosis is focused on inhibiting Chitinase 1 (Chit1) with patented "OCF-203."

Chit1 is also a critical biomarker in Scleroderma-associated interstitial lung disease (SSc-ILD) and plays a role in bleomycin- and IL-13-induced pulmonary fibrosis.

Ocean Biomedical's OCF-203 has shown an 85% – 90% reduction in collagen accumulation in four pulmonary fibrosis animal models.

Results also showed efficacy in the pale-ear mouse model of HPS, including reductions in fibrosis.

Last week, co-founder, Jonathan Kurtis, received a Notice of Allowance from the USPTO for his U.S. patent application covering a therapeutic and prophylactic monoclonal antibody targeting malaria.

Earlier this week, Ocean Biomedical announced $134 million in financial backing.

Price Action: OCEA shares closed at $6.58 on Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article EXCLUSIVE: Ocean Biomedical's Co-Founder Jack Elias To Receive US Patent For Lung Fibrosis Therapeutics originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement